BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25590378)

  • 1. The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells.
    Knops N; van den Heuvel LP; Masereeuw R; Bongaers I; de Loor H; Levtchenko E; Kuypers D
    Mol Pharm; 2015 Mar; 12(3):758-68. PubMed ID: 25590378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus induces a pro-fibrotic response in donor-derived human proximal tubule cells dependent on common variants of the CYP3A5 and ABCB1 genes.
    Knops N; Ramazani Y; De Loor H; Goldschmeding R; Nguyen TQ; van den Heuvel LP; Levtchenko E; Kuypers DJ
    Nephrol Dial Transplant; 2023 Feb; 38(3):599-609. PubMed ID: 35945682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients.
    Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Habuchi T; Suzuki T
    Steroids; 2008 Oct; 73(11):1052-9. PubMed ID: 18502461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis.
    Naito T; Mino Y; Aoki Y; Hirano K; Shimoyama K; Ogawa N; Kagawa Y; Kawakami J
    Clin Chim Acta; 2015 May; 445():79-84. PubMed ID: 25817604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
    Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
    Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation.
    Yanagimachi M; Naruto T; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto H; Yagihashi T; Kosaki K; Yokota S
    Clin Transplant; 2010; 24(6):855-61. PubMed ID: 20030680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.
    Cusinato DA; Lacchini R; Romao EA; Moysés-Neto M; Coelho EB
    Br J Clin Pharmacol; 2014 Aug; 78(2):364-72. PubMed ID: 24528196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus-induced nephrotoxicity and genetic variability: a review.
    Gijsen VM; Madadi P; Dube MP; Hesselink DA; Koren G; de Wildt SN
    Ann Transplant; 2012; 17(2):111-21. PubMed ID: 22743729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A5 genotype-phenotype analysis in the human kidney reveals a strong site-specific expression of CYP3A5 in the proximal tubule in carriers of the CYP3A5*1 allele.
    Bolbrinker J; Seeberg S; Schostak M; Kempkensteffen C; Baelde H; de Heer E; Kreutz R
    Drug Metab Dispos; 2012 Apr; 40(4):639-41. PubMed ID: 22214815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients.
    Quteineh L; Verstuyft C
    Curr Opin Organ Transplant; 2010 Oct; 15(5):601-7. PubMed ID: 20720493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus.
    Yan L; Li Y; Tang JT; An YF; Wang LL; Shi YY
    Pharmacogenomics; 2016 Feb; 17(3):249-57. PubMed ID: 26784512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
    Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
    Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
    Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
    Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation.
    Tapirdamaz Ö; Hesselink DA; el Bouazzaoui S; Azimpour M; Hansen B; van der Laan LJ; Polak WG; Kwekkeboom J; van Schaik RH; van Gelder T; Metselaar HJ
    Pharmacogenet Genomics; 2014 Sep; 24(9):427-35. PubMed ID: 25014506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenotyping of CYP3A5 in predicting dose-adjusted trough levels of tacrolimus among Malaysian kidney-transplant patients.
    Hamzah S; Teh LK; Siew JS; Ahmad G; Wong HS; Zakaria ZA; Salleh MZ
    Can J Physiol Pharmacol; 2014 Jan; 92(1):50-7. PubMed ID: 24383873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.